ClinVar Miner

Submissions for variant NM_170707.4(LMNA):c.1255C>T (p.Arg419Cys)

gnomAD frequency: 0.00004  dbSNP: rs755686359
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000227837 SCV000291547 likely benign Charcot-Marie-Tooth disease type 2 2024-01-14 criteria provided, single submitter clinical testing
Eurofins Ntd Llc (ga) RCV000597022 SCV000704294 uncertain significance not provided 2016-12-21 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV001184022 SCV001349893 uncertain significance Cardiomyopathy 2022-12-07 criteria provided, single submitter clinical testing This missense variant replaces arginine with cysteine at codon 419 of the lamin A/C proteins. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional studies have shown that this variant may affect localization and binding affinity of the lamin A/C protein (PMID: 23977161, 24943589). This variant has been reported in three individuals from a single family affected with partial lipodystrophy and diabetes (PMID: 12716787). It has also been reported in an individual affected with arrhythmogenic right ventricular cardiomyopathy (PMID: 30847666). This variant has been identified in 6/282010 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002479935 SCV002776935 uncertain significance Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome; Dilated cardiomyopathy 1A; Charcot-Marie-Tooth disease type 2B1; Emery-Dreifuss muscular dystrophy 2, autosomal dominant; Heart-hand syndrome, Slovenian type; Hutchinson-Gilford syndrome; Familial partial lipodystrophy, Dunnigan type; Mandibuloacral dysplasia with type A lipodystrophy; Congenital muscular dystrophy due to LMNA mutation; Emery-Dreifuss muscular dystrophy 3, autosomal recessive; Restrictive dermopathy 2 2022-02-16 criteria provided, single submitter clinical testing
All of Us Research Program, National Institutes of Health RCV003998891 SCV004821879 uncertain significance Primary dilated cardiomyopathy 2023-06-27 criteria provided, single submitter clinical testing This missense variant replaces arginine with cysteine at codon 419 of the lamin A/C proteins. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional studies have shown that this variant may affect localization and binding affinity of the lamin A/C protein (PMID: 23977161, 24943589). This variant has been reported in three individuals from a single family affected with partial lipodystrophy and diabetes (PMID: 12716787). It has also been reported in an individual affected with arrhythmogenic right ventricular cardiomyopathy (PMID: 30847666). This variant has been identified in 6/282010 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Ambry Genetics RCV004020899 SCV005030832 uncertain significance Cardiovascular phenotype 2023-09-18 criteria provided, single submitter clinical testing The p.R419C variant (also known as c.1255C>T), located in coding exon 7 of the LMNA gene, results from a C to T substitution at nucleotide position 1255. The arginine at codon 419 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant has been reported in a family with familial partial lipodystrophy, and has been detected in an individual reported to have limb girdle muscular dystrophy (Haque WA et al. Diabetes Care, 2003 May;26:1350-5; Nishikawa A et al. J Med Genet, 2017 Feb;54:104-110). Functional studies indicate this variant may impact protein function (Kiel T et al. Int J Biochem Cell Biol, 2014 Aug;53:271-80). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.